Turkish Ministry of Health Purchases Two CyberKnife(R) Systems

Expands Patient Access to the Benefits of Whole Body Radiosurgery

SUNNYVALE, Calif., June 19 /PRNewswire-FirstCall/ -- Accuray Incorporated
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that the Turkish Ministry of Health has purchased two CyberKnife(R) Robotic
Radiosurgery Systems for installation in Ankara and Istanbul, Turkey.

Turkey's first CyberKnife System was installed at Anadolu Medical Center in
January 2005. A second system was installed in Turkey at Hacettepe University
Hospital in May 2007. In addition to the two recent purchases by the Ministry
of Health, a fifth System for installation within Turkey was recently
purchased by Istanbul University, Oncology Institute, a leading academic
institution in Capa district, Istanbul. The sales of these Systems were
coordinated by local distributor Radontek Ltd.

"The Turkish Ministry of Health's purchase of two CyberKnife Systems is
further validation of the System's worldwide clinical acceptance, particularly
amongst government institutions," said Euan S. Thomson, Ph.D., president and
CEO of Accuray Incorporated. "Full body radiosurgery with the CyberKnife
System has truly established itself as a viable treatment alternative for
cancer patients around the world."

The CyberKnife Systems for Ankara and Instanbul were purchased by the Turkish
Ministry of Health for Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve
Arastirma Hastanesi (Ankara) and Dr. Lutfu Kirdar Kartal Egitim ve Arastirma
Hastanesi (Istanbul).

About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body stabilization
frames.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global
leader in the field of radiosurgery dedicated to providing an improved quality
of life and a non-surgical treatment option for those diagnosed with cancer.
Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which
extends the benefits of radiosurgery to include extracranial tumors, including
those in the spine, lung, prostate, liver and pancreas. To date, the
CyberKnife System has been used to treat more than 60,000 patients worldwide
and currently more than 164 systems have been installed in leading hospitals
in the Americas, Europe and Asia. For more information, please visit
www.accuray.com.

Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
commercialization of products, clinical studies, and regulatory review and
approval are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management's good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2008
fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other
filings with the Securities and Exchange Commission. The Company's actual
results of operations may differ significantly from those contemplated by such
forward-looking statements as a result of these and other factors. We assume
no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.

SOURCE Accuray Incorporated

Stephanie Tomei, Senior Manager, Public Relations, +1-408-789-4234,
stomei@accuray.com, or Sancie Nakarat, Manager, EU MarCom, +33,155,232,028,
snakarat@accuray.com, both of Accuray Incorporated